Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tivozanib has PFS benefit over sorafenib in hard-to-treat RCC

Key clinical point: Tivozanib is efficacious and well tolerated for treating refractory advanced renal cell carcinoma.

Major finding: Median progression-free survival was 5.6 months with tivozanib and 3.9 months with sorafenib (hazard ratio, 0.73; P = .0165).

Study details: A phase 3 open-label, randomized controlled trial among 350 patients with treatment-refractory advanced RCC (TIVO-3 trial).

Disclosures: Dr. Rini reported that he has a consulting role with Aveo, which sponsored the trial, and financial relationships with several other companies.

Citation:

Rini BI et al. GUCS 2019, Abstract 541.